Researchers Found New Malaria Vaccine Target
A discovery in the parasite's protein may offer a path to preventing liver infections that cause recurrent malaria.
Updated on Sept. 24, 2026 in COVID-19
Live Poll
Should the government prioritize funding for new scientific breakthroughs in disease prevention?
Scientists at USF Health have identified a specific vulnerability in the Plasmodium vivax parasite that antibodies can exploit to block liver cell invasion. This finding could prove essential for developing new vaccines to combat a disease that affected 282 million people in 2024.
Why it matters
Malaria can persist in the liver for months or years, leading to recurring infections that are difficult to manage. Identifying this new target offers a potential strategy for preventing the initial stage of infection.
A study published in Immunity identified a key inhibitory epitope on the circumsporozoite protein that prevents parasite invasion of host cells. This marks the first such target discovery on this specific protein in 40 years.
The players
USF Health
An academic medical research center based in Tampa, Florida, focused on advancing public health and clinical breakthroughs.
Immunity
A peer-reviewed scientific journal that publishes influential research regarding the human immune system.
The details
The parasite uses the circumsporozoite protein to gain entry into the human liver, which is the site of early infection. By targeting this vulnerability site with antibodies, scientists aim to stop the parasite before it can successfully invade liver cells. This mechanism is critical because preventing this initial invasion could block the parasite's ability to remain dormant in the body and trigger future relapses.
Timeline
Malaria affected 282 million people globally in 2024.
The research findings were published in the journal Immunity on September 24, 2026.
Health Landscape
The identification of this site sits within the ongoing global push to improve the development of malaria vaccines. This study advances the current field by identifying a long-sought target that could refine the design of future preventative treatments.
This research is currently in the discovery stage and does not change your immediate care or treatment options. If you are traveling to regions where malaria is prevalent, such as parts of Southeast Asia or Central and South America, consult your doctor regarding existing prevention strategies.
The takeaway
Understanding how the malaria parasite invades the liver is a critical step toward ending recurrent infections. Continue to rely on established malaria prophylaxis and mosquito bite prevention when traveling to endemic regions while researchers work toward clinical vaccine trials.
Further reading
For broader context on how researchers identify and test new vaccine targets, visit COVID-19.
Live Poll
Should the government prioritize funding for new scientific breakthroughs in disease prevention?
